More long-term advances will be combining agentsthat work on FMRPmechanisms to give additive therapeutic benefit, and use of gene therapyand other genetic strategies, which are in development, to allow productionof FMRP in brain and correct the primary defect in FXS. The gene discussed is FMR1; the disease is fragile X syndrome.